Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

7.2K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.2K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

461
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
461
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

391
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
391
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.1K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.1K
Clinical Trials: Overview01:11

Clinical Trials: Overview

2.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.5K
Drug Regulation01:25

Drug Regulation

1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

David's Sling: Bioethics Empiricism as Big Tech Goliaths Enter Genomics.

The American journal of bioethics : AJOB·2025
Same author

Ethics choices during the Human Genome Project reflected their policy world, not ours.

Cell genomics·2025
Same author

"I Just Assumed This Was Already Being Done": Canadian Patient Preferences for Enhanced Data Sharing for Precision Oncology.

JCO precision oncology·2024
Same author

Sorry you asked? <i>Mayo, Myriad</i>, and the battles over patent-eligibility.

Journal of law and the biosciences·2024
Same author

Exploring regulatory flexibility to create novel incentives to optimize drug discovery.

Frontiers in medicine·2024
Same author

The <i>Myriad</i> Decision at 10.

Annual review of genomics and human genetics·2024
Same journal

A native sulfur deposit in Gale crater, Mars.

Science (New York, N.Y.)·2026
Same journal

Coordinated demise of harmful algal blooms.

Science (New York, N.Y.)·2026
Same journal

Genetic effects put into context.

Science (New York, N.Y.)·2026
Same journal

Bacteria share proteins to survive antibiotics.

Science (New York, N.Y.)·2026
Same journal

Impacts shaped Earth's first continents.

Science (New York, N.Y.)·2026
Same journal

Erratum for the Report "Covalently bonded single-molecule junctions with stable and reversible photoswitched conductivity" by C. Jia <i>et al</i>.

Science (New York, N.Y.)·2026
See all related articles

Related Experiment Video

Updated: May 15, 2025

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

2.7K

AI drug development's data problem.

E Richard Gold1, Robert Cook-Deegan2

  • 1E. Richard Gold is at the Faculty of Law and Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada; is Chief Policy and Partnerships Officer, Conscience, Toronto, ON, Canada; and is senior fellow, Centre for International Governance Innovation, Waterloo, ON, Canada.

Science (New York, N.Y.)
|April 10, 2025
PubMed
Summary
This summary is machine-generated.

Artificial intelligence (AI) holds promise for drug discovery but requires significant development. Open, high-quality datasets managed by independent organizations are crucial for training and validating AI models to advance the field.

More Related Videos

Author Spotlight: AI-Driven Trypanosome Species Detection from Microscopic Images
08:20

Author Spotlight: AI-Driven Trypanosome Species Detection from Microscopic Images

Published on: October 27, 2023

1.3K
TBase - an Integrated Electronic Health Record and Research Database for Kidney Transplant Recipients
09:00

TBase - an Integrated Electronic Health Record and Research Database for Kidney Transplant Recipients

Published on: April 13, 2021

4.4K

Related Experiment Videos

Last Updated: May 15, 2025

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

2.7K
Author Spotlight: AI-Driven Trypanosome Species Detection from Microscopic Images
08:20

Author Spotlight: AI-Driven Trypanosome Species Detection from Microscopic Images

Published on: October 27, 2023

1.3K
TBase - an Integrated Electronic Health Record and Research Database for Kidney Transplant Recipients
09:00

TBase - an Integrated Electronic Health Record and Research Database for Kidney Transplant Recipients

Published on: April 13, 2021

4.4K

Area of Science:

  • Computational chemistry
  • Bioinformatics
  • Artificial intelligence in medicine

Background:

  • Artificial intelligence (AI) is poised to revolutionize drug discovery.
  • However, AI applications in this field are currently in their nascent stages.

Discussion:

  • The advancement of AI in drug discovery is contingent upon the availability of comprehensive, high-quality datasets.
  • Proprietary data formats and limited access hinder the development and validation of AI models.

Key Insights:

  • Independent organizations should manage large, open-access datasets.
  • These datasets are essential for training and validating AI algorithms effectively.
  • Standardization and accessibility of data are paramount for AI maturation in drug discovery.

Outlook:

  • Facilitating open data initiatives will accelerate AI's integration into pharmaceutical research.
  • Collaborative efforts are needed to build robust, generalizable AI models for drug development.
  • The future of AI in drug discovery depends on addressing current data limitations.